Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
Nicholas C. Turner, Yuan Liu, Zhou Zhu, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 14, pp. 1169-1178
Open Access | Times Cited: 355

Showing 1-25 of 355 citing articles:

Targeting cell-cycle machinery in cancer
Jan M. Suski, Marcin Braun, Vladislav Strmiska, et al.
Cancer Cell (2021) Vol. 39, Iss. 6, pp. 759-778
Open Access | Times Cited: 379
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M. Spring, Seth A. Wander, Fabrice André, et al.
The Lancet (2020) Vol. 395, Iss. 10226, pp. 817-827
Closed Access | Times Cited: 372
Targeting CDK4 and CDK6 in cancer
Shom Goel, Johann S. Bergholz, Jean J. Zhao
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 356-372
Open Access | Times Cited: 321
CDK4 and CDK6 kinases: From basic science to cancer therapy
Anne Fassl, Yan Geng, Piotr Siciński
Science (2022) Vol. 375, Iss. 6577
Open Access | Times Cited: 307
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal, Elisabeth M. Jongbloed, Saskia M. Wilting, et al.
Drugs (2020) Vol. 81, Iss. 3, pp. 317-331
Open Access | Times Cited: 300
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Mónica Álvarez‐Fernández, Marcos Malumbres
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 514-529
Open Access | Times Cited: 283
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
Seth A. Wander, Ofir Cohen, Xueqian Gong, et al.
Cancer Discovery (2020) Vol. 10, Iss. 8, pp. 1174-1193
Open Access | Times Cited: 275
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao, Joyce Cheng, Erik Bloomquist, et al.
The Lancet Oncology (2019) Vol. 21, Iss. 2, pp. 250-260
Closed Access | Times Cited: 242
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L. Mayer, Amylou C. Dueck, Miguel Martín, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 2, pp. 212-222
Closed Access | Times Cited: 224
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner, Caitlin E. Mills, Kartik Subramanian, et al.
Cell chemical biology (2019) Vol. 26, Iss. 8, pp. 1067-1080.e8
Open Access | Times Cited: 213
Integrating Old and New Paradigms of G1/S Control
Seth M. Rubin, Julien Sage, Jan M. Skotheim
Molecular Cell (2020) Vol. 80, Iss. 2, pp. 183-192
Open Access | Times Cited: 207
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa, Ye Wang, Amy Ly, et al.
Cancer Discovery (2019) Vol. 10, Iss. 1, pp. 72-85
Open Access | Times Cited: 204
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Sara A. Hurvitz, Miguel Martín, Michael F. Press, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 3, pp. 566-580
Open Access | Times Cited: 180
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Erik S. Knudsen, Steven C. Pruitt, Pamela A. Hershberger, et al.
Trends in cancer (2019) Vol. 5, Iss. 5, pp. 308-324
Open Access | Times Cited: 162
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Ugo Testa, Germana Castelli, Elvira Pelosi
Medical Sciences (2020) Vol. 8, Iss. 1, pp. 18-18
Open Access | Times Cited: 160
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
Amelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 146
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller, et al.
Cancer Cell (2021) Vol. 39, Iss. 10, pp. 1404-1421.e11
Closed Access | Times Cited: 131
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Aleix Prat, Anwesha Chaudhury, Nadia Solovieff, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 13, pp. 1458-1467
Open Access | Times Cited: 120
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
Mridula George, Sadaf Qureshi, Coral Omene, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 115
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 24, pp. 4004-4013
Closed Access | Times Cited: 104
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C. Watt, Shom Goel
Breast Cancer Research (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 87
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
Erik S. Knudsen, Vishnu Kumarasamy, Ram Nambiar, et al.
Cell Reports (2022) Vol. 38, Iss. 9, pp. 110448-110448
Open Access | Times Cited: 86
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
Mansi Arora, Justin Moser, Timothy E. Hoffman, et al.
Cell (2023) Vol. 186, Iss. 12, pp. 2628-2643.e21
Open Access | Times Cited: 72
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Fabrice André, Faye Su, Nadia Solovieff, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 1003-1014
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top